Harbour BioMed’s AI-Enabled Obesity Antibody LET003 Has IND Accepted

Harbour BioMed announced on November 18, 2026 that China’s National Medical Products Administration had accepted the investigational new drug (IND) application for LET003, its first drug candidate developed using the Hu-mAtrIx AI platform. The monoclonal antibody is intended to treat overweight or obesity by blocking the activin receptors ACVR2A and ACVR2B. The milestone is acceptance of an application to enter clinical development, not a reported clinical result. The efficacy findings in the…

Leave a Reply

Your email address will not be published. Required fields are marked *

Back To Top